MD Anderson researcher elected to ASCO Board of Directors
Mariana Chavez Mac Gregor, M.D., M.Sc., associate professor in Health Services Research with a joint appointment in Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, has been elected to the American Society of Clinical Oncology (ASCO) Board of Directors. Members of the board are elected by ASCO’s members. Those who serve in these roles are cancer physicians and clinical researchers who volunteer...
CAR T cell therapy effective as first-line treatment for high-risk large B-cell lymphoma
ABSTRACT 405
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19...
Five MD Anderson researchers elected AAAS Fellows
In recognition of their achievements in advancing cancer research, five faculty members from The University of Texas MD Anderson ...
MD Anderson joins thousands of top U.S. hospitals encouraging everyone to #MaskUp
The University of Texas MD Anderson Cancer Center and more than 100 of the nation’s top health care systems, representing thousands of hospitals in communities across the U.S., came together on an urgent plea for all Americans to mask up, because wearing a face mask is our best chance at slowing the surging COVID-19 pandemic now.
More than 11.5 million Americans have tested positive for the virus – including an additional 1 million...
A Conversation With a Living Legend honoring Admiral William H. McRaven raises $1 million
The North Texas A Conversation With a Living Legend® raised $1 million this week in a virtual version of the signature fundraising event benefiting...
Sherry Adkins receives Brown Foundation Award for Excellence in Oncology Nursing
Sherry Adkins is the recipient of the 2020 Brown Foundation Award for Excellence in Oncology Nursing at The University of Texas MD Anderson...
MD Anderson announces fifth annual class of Andrew Sabin Family Fellows
The University of Texas MD Anderson Cancer Center has named 10 early-career faculty members to the 2020 class of Andrew Sabin Family Fellows...
MD Anderson and UT Austin collaboration to end cancer welcomed enthusiastically by state and federal stakeholders
A new collaboration combining cancer research with advanced computing and computational modeling techniques received strong engagement and...
MD Anderson earns fifth Magnet designation for nursing excellence
The University of Texas MD Anderson Cancer Center today announced achievement of its fifth consecutive Magnet designation, the highest distinction...
Study identifies characteristics of infused CAR T cells associated with efficacy and toxicity in patients with large B-cell lymphoma
Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19...
New study from MD Anderson and BridgeBio’s Navire Pharma shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc...
Combination immunotherapy benefits subset of patients with advanced prostate cancer
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab...
$24 million in CPRIT funding awarded to MD Anderson and related research
The University of Texas MD Anderson Cancer Center today was awarded nearly $9 million from the Cancer Prevention and Research Institute...
Combination therapy significantly improves survival outcomes for patients with acute myeloid leukemia
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients...
Public Notice of Scheduled Site Visit to MD Anderson by ANCC Magnet Recognition Program Appraisers
Public Notice
MAGNET RECOGNITION PROGRAM® — SITE VISIT
· The University of Texas...
Combination therapy well-tolerated and highly effective for patients with IDH1-mutated acute myeloid leukemia (AML)
ABSTRACT: #7500
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective...
MD Anderson implements proactive measures due to 2019 novel coronavirus disease (COVID-19)
The University of Texas MD Anderson Cancer Center is committed to keeping our patients, our workforce members and our community safe throughout...
Combined therapy may improve clinical responses for endometrial, colorectal and gastric tumors
A study at The University of Texas MD Anderson Cancer Center discovered a novel therapeutic vulnerability for patients who have tumors caused...
B-cell enrichment predictive of immunotherapy response in melanoma, sarcoma and kidney cancer
The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within specialized immune-cell...
Study shows protein inhibitor as potential treatment approach for common mutations found in non-Hodgkin lymphomas
A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common subtypes...